Introduction: The lack of an accurate blood biomarker in neuroendocrine tumor (NET) disease impedes effective management.
Aim(s): Review published data of a blood mRNA-based NET biomarker, the NETest.
Materials and methods: A systematic review using PRISMA guidelines. Ten original scientific papers, were identified. These were assessed by qualitative and then meta-analysis. Data were pooled and median (95% confidence interval [CI]) diagnostic odds ratio (DOR), positive likelihood ratio (+LR) and negative likelihood ratio (–LR) calculated. For the meta-analysis, a generic inverse variance method was undertaken using the accuracy and area under the curve (AUC) data.
Conference: 17th Annual ENETS Conference 2020 (2020)
Presenting Author: MD, PhD Lisa Bodei
, Califano A
, Strosberg J
, Ma S
, Pape U F
, Bodei L
, Kaltsas G
, Toumpanakis C
, Goldenring J
, Frilling A
, Paulson S
To read results and conclusion, please login ...
Further abstracts you may be interested in